GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:18 15/01/2025 GMT			5-day change	1st Jan Change
1,327.50 ^GBX	+2.63%		-2.39%	-1.41%

01-15	GSK : JP Morgan reiterates its Sell rating	ZD
01-15	Haleon: Pfizer continues to withdraw from the capital	CF

GSK : Deutsche Bank remains Neutral

January 10, 2025 at 11:12 am

In a research note, Deutsche Bank analyst Emmanuel Papadakis has maintained his recommendation on the stock with a Neutral rating. The target price continues to be set at GBX 1350.

Latest news about GSK plc

GSK : JP Morgan reiterates its Sell rating	01-15	ZD
Haleon: Pfizer continues to withdraw from the capital	01-15	CF
Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale	01-15	AN
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion	01-15	DJ
Pfizer to more than halve Haleon holding in GBP2.57 billion sale	01-14	AN
GSK plc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 07:30 AM	01-14
GSK Acquiring US-Based IDRx for up to $1.15 Billion	01-13	MT
GSK CEO on US Expansion, M&A, Drug Pipeline, Trump	01-13	MT
London Stocks Start Week With Losses as Rate Cut Hopes Dim	01-13	MT
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	01-13
GSK to Bolster Gastrointestinal Cancer Portfolio With Up to $1.2 Billion Acquisition of US Biopharmaceutical	01-13	MT
Illumina Starts Pilot Program With Partners to Generate Proteomics Data	01-13	MT
GSK to buy precision therapeutics firm IDRx for up to USD1.15 billion	01-13	AN
FTSE 100 down, Reeves fails to lift mood	01-13	AN
FTSE 100 : Entain and oil stocks can't stop London indices' drop	01-13
GSK to Acquire Oncology Firm IDRx for Up to $1.15 Billion	01-13	MT
GSK: agreement to acquire IDRx	01-13	CF
Stocks red, China exports surge before Trump tariffs	01-13	AN
GSK to Buy US-based IDRx for Up to $1.15 Billion to Boost Gastrointestinal Cancer Pipeline	01-13	MT
GSK to Buy US-based IDRx for $1.15 Billion in Boost for Gastrointestinal Cancer Pipeline	01-13	MT
GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion	01-13	DJ
GSK to buy US biotech firm IDRx for up to $1.15 billion	01-13	RE
GSK plc entered into an agreement to acquire IDRX, Inc. for approximately $1.2 billion.	01-12	CI
Us Food and Drug Administration Accepts GSK Plc's Shingrix New Prefilled Syringe Presentation of Shingrix for the Prevention of Shingles (Herpes Zoster)	01-10	CI
GSK : Deutsche Bank remains Neutral	01-10	ZD

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

70,212

Sector

Pharmaceuticals

Calendar

05/02/2025 - Q4 2024 Earnings Release

More about the company